|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The gene expression profiling identified dysregulation of developmentally related genes, including the downstream targets of polycomb repressive complex 2 (PRC2) and overexpression of enhancer of zeste homolog 2, a component of PRC2, in the carcinomas.
|
29435983 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ARID1A-depletion did neither increase EZH2 protein or trimethylated H3K27 levels in vitro nor did ARID1A expression correlate with EZH2 or H3K27me3 amounts in human bladder carcinomas.
|
30138427 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EZH2 is an important enzymatic subunit of the epigenetic regulator polycomb repressive complex 2 (PRC2), which controls gene silencing through post-translational modification, and is overexpressed in various carcinomas and hematopoietic neoplasms.
|
29327713 |
2018 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Here we show that in human invasive carcinomas and distant metastases, cytoplasmic EZH2 phosphorylated at T367 is significantly associated with ER- disease and low H3K27me3 levels. p38-mediated EZH2 phosphorylation at T367 promotes EZH2 cytoplasmic localization and potentiates EZH2 binding to vinculin and other cytoskeletal regulators of cell migration and invasion.
|
30022044 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Investigation of the expression of EZH2 in canine mammary tumors revealed that EZH2 protein was overexpressed in canine mammary carcinomas, as in human breast cancer.
|
27502594 |
2016 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of EZH2 was seen in all cases of cholangiolocellular carcinomas, while it was not observed in bile duct adenomas or ductular reactions.
|
25289642 |
2015 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Enhancer of zeste homolog 2 (EZH2) mediated down-regulation of CDKN2A/p16 has been observed in cell lines as well as in a few carcinomas.
|
26096306 |
2015 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of EZH2 inhibits growth of ovarian cancer as well as other human carcinomas.
|
24771265 |
2014 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consonant with these findings, in clinical samples, high levels of EZH2 are significantly associated with activated NOTCH1 protein and increased TICs in TN invasive carcinomas.
|
24516139 |
2014 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase mediating chromatin condensation and epigenetic modulation, is overexpressed in various human carcinomas and is associated with adverse clinicopathologic characteristics and biologic behavior.
|
24079759 |
2013 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As a key component of polycomb-repressive complex 2, enhancer of zeste homolog 2 (EZH2) represses target genes through histone methylation and is frequently overexpressed and associated with poor prognosis in common carcinomas.
|
21300475 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EZH2 overexpression is commonly associated with poor prognosis in a variety of tumor types including carcinomas, lymphomas and soft tissue sarcomas.
|
23110793 |
2012 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A group of 169 breast tissues (100 invasive carcinomas and 69 benign) from women treated at Komfo Anoyke Teaching Hospital between 2006 and 2011 were histologically classified and investigated for EZH2 expression.
|
22527102 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mechanism by which EZH2 overexpression promotes the growth of poorly differentiated invasive carcinomas remains to be defined.
|
21406404 |
2011 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A recently discovered histone methyltransferase termed enhancer of zeste homologue 2 (EZH2) was found to be overexpressed in a variety of carcinomas including pancreatic adenocarcinoma.
|
20573371 |
2010 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EZH2 was overexpressed in pancreatic carcinomas and its overexpression was associated with tumor differentiation and pT status.
|
20684863 |
2010 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The polycomb group genes Bmi1 polycomb ring finger oncogene (Bmi1) and enhancer of zeste homolog 2 (EZH2) function as transcriptional repressors involved in gene silencing and in the malignant transformation and biologic aggressiveness of several human carcinomas.
|
20564407 |
2010 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High EZH2 expression was related to an abbreviated time to recurrence in muscle invasive carcinomas (pT >/= 2) (P = 0.028).
|
17694325 |
2008 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Polycomb-group proteins Bmi1 and EZH2 are involved in the malignant transformation and biological aggressiveness of several human carcinomas.
|
18591938 |
2008 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, expression levels of EZH2 are elevated in aggressive and invasive urothelial carcinomas, suggesting that deregulated EZH2 expression may be involved in the progression of bladder tumors.
|
16012774 |
2005 |